Erratum to From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management

The originally published version of this article¹ contained errors in the section “Cross-platform MRD detection: thresholds and positivity standards” on page 1499. The authors reported incorrect data for the limit of detection (LoD) in this section. The LoD of the Signatera^® (Natera) assay is 0.01% variant allele frequency (VAF). For the Signatera Genome assay, no LoD data have been publicly reported, and therefore the LoD claim for this assay has been removed. In this section, the authors’ intention was to compare the thresholds and positivity criteria of different platforms for detection of minimal residual disease (MRD). These errors do not affect the conclusions of the article. The authors apologize for these errors and for any confusion caused.

The corrected first paragraph of the section Cross-platform MRD detection: thresholds and positivity standards is presented below.

Positivity criteria vary across various MRD detection technologies. Signatera^® (Natera), a tumor-informed multiplex PCR assay, customizes a personalization panel of as many as 16 somatic mutations, with a median of 11 (range 8–16), derived from WES of tumor tissue. MRD positivity is defined as the detection of ≥2 tumor-specific mutations, with a LoD95 of 0.01% VAF^61,62. In contrast, the Signatera Genome assay uses WGS to identify and monitor as many as 64 patient-specific somatic mutations from tumor tissue, a number representing an expansion beyond its original 16-mutation panel. The assay uses mPCR with a sensitivity of low single-digit ppm levels and maintains the same validated chemistry as the original Signatera platform. With customized primers, serial blood-based ctDNA detection achieves MRD positivity determination via a proprietary sample-calling algorithm that compares target confidences against sample-level noise.

• Received September 2, 2026.
• Accepted September 2, 2026.

• Copyright: © 2026, The Authors